 Zynerba Pharmaceuticals Inc NASDAQ: ZYNE presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental epileptic encephalopathies DEE and autism spectrum disorder ASD. Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting. 